Erba Transasia, a global major in providing innovative diagnostic solutions has taken a significant step forward in public health by launching India's first indigenously manufactured ErbaMDx MonkeyPox RT-PCR Kit.  These test kits are produced at Transasia Diagnostic Pvt Ltd. (TDPL) in the Andhra Pradesh MedTech Zone (AMTZ) Visakhapatnam with a manufacturing of capability of 50 million test kits per month. 

Indian Council for Medical Research (ICMR) has approved the Monkeypox RT-PCR kit after validation and it received the emergency authorization from the Central Drugs Standard Control Organization (CDSCO) under operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India.

The newly released Kit represents a major advancement in diagnostic technology, offering a highly accurate confirmatory test kit and is a timely released armor to detect Mpox in the light of Monkeypox being declared as a public health emergency of international concern by WHO. The kit is designed to eliminate cross-reactivity with other orthopox viruses or organisms, further enhancing its diagnostic precision.

Suresh Vazirani, Founder Chairman, Erba Transasia Group, said, "As a leading manufacturer of clinical diagnostic solutions, we are committed to utilizing our well- established manufacturing and rapid response capabilities to strengthen epidemic preparedness and increase access to life-saving diagnostics for those who need them most at an affordable price” He also pointed that “The most notable aspects of the ErbaMDx kit is its cost-effectiveness and accessibility. The kit's lyophilized components allow for shipping and storage at ambient temperatures, making it particularly beneficial for regions with limited cold chain infrastructure. This feature significantly expands access to reliable diagnostics in underserved areas, helping to address healthcare disparities during critical outbreaks.”